Limits...
The usefulness of F-18 FDG PET/CT-mammography for preoperative staging of breast cancer: comparison with conventional PET/CT and MR-mammography.

Moon EH, Lim ST, Han YH, Jeong YJ, Kang YH, Jeong HJ, Sohn MH - Radiol Oncol (2013)

Bottom Line: No significant difference was found in the number of metastatic axillary lymph nodes.In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MR-mammography showed correspondence with pathologic results.Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, Korea ; Department of Nuclear Medicine, Presbyterian Medical Center, Jeonju, Jeonbuk, Korea.

ABSTRACT

Background: The objective of the study was to compare the diagnostic efficacy of an integrated Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT-mammography (mammo-PET/CT) with conventional torso PET/CT (supine-PET/CT) and MR-mammography for initial assessment of breast cancer patients.

Patients and methods: Forty women (52.0 ± 12.0 years) with breast cancer who underwent supine-PET/CT, mammo-PET/CT, and MR-mammography from April 2009 to August 2009 were enrolled in the study. We compared the size of the tumour, tumour to chest wall distance, tumour to skin distance, volume of axillary fossa, and number of meta-static axillary lymph nodes between supine-PET/CT and mammo-PET/CT. Next, we assessed the difference of focality of primary breast tumour and tumour size in mammo-PET/CT and MR-mammography. Histopathologic findings served as the standard of reference.

Results: In the comparison between supine-PET/CT and mammo-PET/CT, significant differences were found in the tumour size (supine-PET/CT: 1.3 ± 0.6 cm, mammo-PET/CT: 1.5 ± 0.6 cm, p < 0.001), tumour to thoracic wall distance (1.8 ± 0.9 cm, 2.2 ± 2.1 cm, p < 0.001), and tumour to skin distance (1.5 ± 0.8 cm, 2.1 ± 1.4 cm, p < 0.001). The volume of axillary fossa was significantly wider in mammo-PET/CT than supine-PET/CT (21.7 ± 8.7 cm(3) vs. 23.4 ± 10.4 cm(3), p = 0.03). Mammo-PET/CT provided more correct definition of the T-stage of the primary tumour than did supine-PET/CT (72.5% vs. 67.5%). No significant difference was found in the number of metastatic axillary lymph nodes. Compared with MR-mammography, mammo-PET/CT provided more correct classification of the focality of lesion than did MR-mammography (95% vs. 90%). In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MR-mammography showed correspondence with pathologic results.

Conclusions: Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT. The initial assessment of mammo-PET/CT would be more useful than MR-mammography because the mammo-PET/CT indicates similar accuracy with MR-mammography for decision of T-stage of primary breast tumour and more correct than MR-mammography for defining focality of lesion.

No MeSH data available.


Related in: MedlinePlus

Breast positioning device. The device is constructed for prone breast positioning.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3814285&req=5

f1-rado-47-04-390: Breast positioning device. The device is constructed for prone breast positioning.

Mentions: Whole body F-18 FDG PET/CT scans were obtained on a BiographTruepoint 40 PET/CT (Siemens, Berlin, Germany). Patients fasted for at least 6 hours before receiving an intravenous injection of F-18 FDG (mean: 429.0 ± 59.0 MBq (11.6 ± 1.6 mCi), range: 259.0 – 592.0 MBq (7 – 16 mCi)). Prior to injection of F-18 FDG, blood glucose levels were checked in order to determine whether the levels were within the reference range (< 150 mg/dL). PET/CT images were acquired at 50 – 60 minutes after intravenous administration of F-18 FDG. Torso PET/CT from the skull base to the upper thigh was performed while the patient was in supine position (5 bed position, 120 seconds per bed). An iodinated contrast agent containing 320 mg of iodine per millilitre was injected using an automated injector (2.0 ml/kg body weight at an injection rate of 1.6 ml/s). A limited breath-hold technique was used in order to avoid motion-induced artifacts near the diaphragm. Then, mammo-PET/CT was performed after repositioning the patient prone (2 bed position, 120 seconds per bed), using a special breast-positioning device (E-cam scintimammography pallet, Siemens) (Figure 1). That device allowed for a breast position similar to that for the MR-mammography used in a routine clinical setting. Mammo-PET/CT image acquisition started at approximately 75 minutes after intravenous injection of F-18 FDG. The PET images were reconstructed by standard 3D-iterative algorithm (ordered subset expectation maximization; OSEM).


The usefulness of F-18 FDG PET/CT-mammography for preoperative staging of breast cancer: comparison with conventional PET/CT and MR-mammography.

Moon EH, Lim ST, Han YH, Jeong YJ, Kang YH, Jeong HJ, Sohn MH - Radiol Oncol (2013)

Breast positioning device. The device is constructed for prone breast positioning.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3814285&req=5

f1-rado-47-04-390: Breast positioning device. The device is constructed for prone breast positioning.
Mentions: Whole body F-18 FDG PET/CT scans were obtained on a BiographTruepoint 40 PET/CT (Siemens, Berlin, Germany). Patients fasted for at least 6 hours before receiving an intravenous injection of F-18 FDG (mean: 429.0 ± 59.0 MBq (11.6 ± 1.6 mCi), range: 259.0 – 592.0 MBq (7 – 16 mCi)). Prior to injection of F-18 FDG, blood glucose levels were checked in order to determine whether the levels were within the reference range (< 150 mg/dL). PET/CT images were acquired at 50 – 60 minutes after intravenous administration of F-18 FDG. Torso PET/CT from the skull base to the upper thigh was performed while the patient was in supine position (5 bed position, 120 seconds per bed). An iodinated contrast agent containing 320 mg of iodine per millilitre was injected using an automated injector (2.0 ml/kg body weight at an injection rate of 1.6 ml/s). A limited breath-hold technique was used in order to avoid motion-induced artifacts near the diaphragm. Then, mammo-PET/CT was performed after repositioning the patient prone (2 bed position, 120 seconds per bed), using a special breast-positioning device (E-cam scintimammography pallet, Siemens) (Figure 1). That device allowed for a breast position similar to that for the MR-mammography used in a routine clinical setting. Mammo-PET/CT image acquisition started at approximately 75 minutes after intravenous injection of F-18 FDG. The PET images were reconstructed by standard 3D-iterative algorithm (ordered subset expectation maximization; OSEM).

Bottom Line: No significant difference was found in the number of metastatic axillary lymph nodes.In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MR-mammography showed correspondence with pathologic results.Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, Korea ; Department of Nuclear Medicine, Presbyterian Medical Center, Jeonju, Jeonbuk, Korea.

ABSTRACT

Background: The objective of the study was to compare the diagnostic efficacy of an integrated Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT-mammography (mammo-PET/CT) with conventional torso PET/CT (supine-PET/CT) and MR-mammography for initial assessment of breast cancer patients.

Patients and methods: Forty women (52.0 ± 12.0 years) with breast cancer who underwent supine-PET/CT, mammo-PET/CT, and MR-mammography from April 2009 to August 2009 were enrolled in the study. We compared the size of the tumour, tumour to chest wall distance, tumour to skin distance, volume of axillary fossa, and number of meta-static axillary lymph nodes between supine-PET/CT and mammo-PET/CT. Next, we assessed the difference of focality of primary breast tumour and tumour size in mammo-PET/CT and MR-mammography. Histopathologic findings served as the standard of reference.

Results: In the comparison between supine-PET/CT and mammo-PET/CT, significant differences were found in the tumour size (supine-PET/CT: 1.3 ± 0.6 cm, mammo-PET/CT: 1.5 ± 0.6 cm, p < 0.001), tumour to thoracic wall distance (1.8 ± 0.9 cm, 2.2 ± 2.1 cm, p < 0.001), and tumour to skin distance (1.5 ± 0.8 cm, 2.1 ± 1.4 cm, p < 0.001). The volume of axillary fossa was significantly wider in mammo-PET/CT than supine-PET/CT (21.7 ± 8.7 cm(3) vs. 23.4 ± 10.4 cm(3), p = 0.03). Mammo-PET/CT provided more correct definition of the T-stage of the primary tumour than did supine-PET/CT (72.5% vs. 67.5%). No significant difference was found in the number of metastatic axillary lymph nodes. Compared with MR-mammography, mammo-PET/CT provided more correct classification of the focality of lesion than did MR-mammography (95% vs. 90%). In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MR-mammography showed correspondence with pathologic results.

Conclusions: Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT. The initial assessment of mammo-PET/CT would be more useful than MR-mammography because the mammo-PET/CT indicates similar accuracy with MR-mammography for decision of T-stage of primary breast tumour and more correct than MR-mammography for defining focality of lesion.

No MeSH data available.


Related in: MedlinePlus